Clinical Trials Logo

Parkinson Disease Psychosis clinical trials

View clinical trials related to Parkinson Disease Psychosis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05240339 Completed - Parkinson Disease Clinical Trials

Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)

Start date: April 25, 2019
Phase:
Study type: Observational

Parkinson's disease psychosis encompasses a range of symptoms, including minor phenomena, frank hallucinations, and delusions. Minor phenomena include passage hallucinations (fleeting sense of a person, animal or object passing in the periphery), presence hallucinations (feeling of nearby presence), and illusions (misrepresentation of external stimuli). Some forms of PD psychosis may be progressive. The primary objective of this study is to: 1) To determine the cumulative probability of developing hallucinations or delusions over time in individuals with PD minor phenomena followed for 36 months.

NCT ID: NCT04292223 Completed - Clinical trials for Parkinson Disease Psychosis

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Start date: February 10, 2020
Phase: Phase 4
Study type: Interventional

To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis

NCT ID: NCT02969369 Completed - Clinical trials for Parkinson Disease Psychosis

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

Start date: December 31, 2016
Phase: Phase 2
Study type: Interventional

A study to evaluate the safety and tolerability of SEP-363856 in subjects with Parkinson's Disease Psychosis. This study is accepting male and female participants 55 years of age and older who have been diagnosed with Parkinson's Disease. This study will be conducted in 24 study centers in the United States. The study will last approximately 21 weeks.